Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)

Objectives: To evaluate the cost-effectiveness of insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) in basal–bolus regimens for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk based on the DEVOTE CV outcomes trial. Methods: A microsimulation model,...

Full description

Bibliographic Details
Main Authors: Andersen, A. (Author), Buse, J.B (Author), Gundgaard, J. (Author), Hallén, N. (Author), Magnuson, E.A (Author), Marso, S.P (Author), Pollock, R.F (Author), the DEVOTE study group (Author), Tutkunkardas, D. (Author), Valentine, W.J (Author)
Format: Article
Language:English
Published: Springer International Publishing 2019
Subjects:
adult
aged
Aged
antidiabetic agent
Article
cardiovascular disease
cerebrovascular accident
clinical outcome
clinical trial
controlled study
cost benefit analysis
cost effectiveness analysis
Cost-Benefit Analysis
Diabetes Mellitus, Type 2
disease severity
double blind procedure
Double-Blind Method
drug efficacy
economics
female
Female
heart infarction
hemoglobin A1c
human
Humans
hypoglycemia
Hypoglycemic Agents
incidence
insulin degludec
insulin glargine
Insulin Glargine
insulin treatment
Insulin, Long-Acting
long acting insulin
long term care
major clinical study
male
Male
middle aged
Middle Aged
Monte Carlo method
Monte Carlo Method
multicenter study
national health service
non insulin dependent diabetes mellitus
phase 3 clinical trial
quality adjusted life year
quality of life
Quality-Adjusted Life Years
randomized controlled trial
sensitivity analysis
State Medicine
treatment duration
United Kingdom
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items